Mission Statement, Vision, & Core Values (2026) of Simcere Pharmaceutical Group Limited.

Founded in 1995, Simcere Pharmaceutical Group Limited has grown into an innovation-driven powerhouse in China's pharma sector with a market capitalization of HKD 33.35 billion (as of December 16, 2025), a 2024 revenue of RMB 6.64 billion (up 0.41% year-on-year) and net income of RMB 733.16 million (up 2.57%), while advancing a clear mission-"for patients, for life"-through flagship products like Sanbexin, Endostar and ENW, the establishment of the State Key Laboratory of Neurology and Oncology Drug Development, and strategic global collaborations such as granting AbbVie an option to license SIM0500 for markets outside China, all driven by core values of Integrity, Innovation, Collaboration, Accountability and Social Responsibility that underpin its vision to expand patient access, global reach and sustainable, patient-centric R&D.

Simcere Pharmaceutical Group Limited (2096.HK) - Intro

• Founded: 1995
• Listing: Hong Kong (2096.HK)
• Key therapeutic areas: Oncology, CNS, autoimmune, anti-infection, cardiovascular
• Principal products: Sanbexin, Endostar, ENW
• Distribution channels: distributors, pharmacy chains, pharmaceutical manufacturers

Mission

Vision

Core values

• Innovation: continuous investment in R&D and translational platforms (e.g., establishment of the State Key Laboratory of Neurology and Oncology Drug Development).
• Integrity: ethical conduct in clinical, regulatory and commercial activities.
• Patient first: prioritize clinical benefit, access and affordability.
• Collaboration: seek strategic alliances and licensing to broaden patient reach (illustrated by the AbbVie option on SIM0500).
• Operational excellence: ensure high-quality manufacturing and distribution to support scalable commercialization.

Selected financial and market snapshot

R&D & strategic initiatives

• State Key Laboratory of Neurology and Oncology Drug Development - a core institutional platform signaling long-term commitment to translational research and high-priority therapeutic areas.
• Global partnering strategy - example: option granted to AbbVie on SIM0500 for blood cancer indications outside China, demonstrating an outward licensing approach to accelerate global reach.
• Product development mix - balanced between proprietary small molecules/biologics in oncology and specialty therapies, and commercialized products generating recurring revenue.

Simcere Pharmaceutical Group Limited (2096.HK) - Overview

Mission: 'for patients, for life' - Simcere Pharmaceutical Group Limited (2096.HK) centers its corporate purpose on improving patient health and quality of life through discovery, development and commercialization of innovative therapies. This mission shapes strategic R&D allocation, partnership choices and ethical governance across the organization.

• Patient-centric focus: prioritize development of novel drugs addressing high unmet clinical needs across oncology, neurology and specialty care.
• Accessibility & efficacy: pursue treatments that balance clinical benefit with broad patient access in China and select global markets.
• Responsible operations: commit to ethical practices, regulatory transparency and safety in clinical development and commercialization.

Strategic R&D and translation-to-clinic efforts directly reflect the mission:

• State Key Laboratory of Neurology and Oncology Drug Development - established to accelerate bench-to-bedside translation by providing integrated medicinal chemistry, translational pharmacology and early clinical development capabilities.
• Partnerships: strategic collaborations with biotech innovators, academic institutes and contract research organizations expand Simcere's pipeline breadth and de-risk late-stage assets.
• Clinical focus: prioritization of candidates with potential to address major disease burdens in China (e.g., lung, liver and colorectal cancers; neurodegenerative and CNS disorders).

How the mission translates into operational actions:

• Pipeline prioritization: resources focused on assets with clear clinical differentiation and population-level impact potential.
• State Key Lab outputs: shortened timelines for lead optimization, IND-enabling studies and first-in-human programs through integrated capabilities.
• Collaborative network: co-development and licensing deals accelerate access to novel modalities (e.g., targeted therapies, ADCs, CNS small molecules).
• Commercial access strategies: pricing, reimbursement engagement and local manufacturing to support patient access across China's hospital and retail channels.

Governance and ethical commitments tied to the mission:

• Regulatory compliance: adherence to NMPA, CFDA legacy requirements and international clinical standards in trial conduct.
• Transparency: public disclosure of clinical trial status, safety data and material agreements consistent with investor and patient expectations.
• Sustainability & CSR: programs aimed at increasing access to essential medicines and supporting patient advocacy groups in key disease areas.

For a financial-focused breakdown of Simcere's health and investor-relevant metrics, see: Breaking Down Simcere Pharmaceutical Group Limited Financial Health: Key Insights for Investors

Simcere Pharmaceutical Group Limited (2096.HK) - Mission Statement

• Expanding global presence through strategic licensing and collaborations - exemplified by the partnership with AbbVie for the licensing of SIM0500 to accelerate development and commercialization globally.
• Enhancing drug accessibility and healthcare coverage by bringing innovative therapies to wider domestic and international markets, prioritizing affordability and reimbursement pathways.
• Building a healthy, diverse workplace via continuous talent development, structured career pathways, and inclusive recruitment across R&D, medical affairs, and commercial functions.
• Committing to green, low-carbon development: adopting pollution control measures, improving resource efficiency, and promoting green supply-chain initiatives across manufacturing and distribution.
• Advancing community-focused initiatives including healthcare assistance programs, education support, and targeted community care projects to build a brighter future.

• Innovation: Maintain and grow R&D intensity to support novel NMEs, biologics, and biosimilars.
• Globalization: Use partnerships and licensing to enter new markets and accelerate late-stage assets.
• Access: Expand patient access through pricing strategies, patient assistance programs, and payer engagement.
• People: Invest in talent development with measurable retention and promotion metrics.
• Sustainability: Reduce carbon footprint and waste intensity per unit of output year-on-year.

• Prioritize first-in-class and best-in-class assets, including oncology and immunology programs.
• Advance late-stage candidates via external partnerships to de-risk development timelines and tap global commercialization channels.
• Target higher R&D productivity measured by INDs, clinical trial enrollments, and out-licensing milestones.

• Green operations: ongoing initiatives to reduce energy intensity and improve waste management across manufacturing sites.
• Supply chain: enforce green procurement standards and supplier audits to lower the environmental footprint of sourced materials.
• Community impact: funding healthcare assistance, patient support programs, and educational outreach to underserved regions.

• Structured career pathways: rotation programs across R&D, regulatory, and commercial functions to build cross-functional leaders.
• Continuous learning: internal academies, external partnerships with universities, and funded certifications.
• Diversity & inclusion: recruitment targets and retention metrics to ensure a broad talent base and equitable advancement.

Simcere Pharmaceutical Group Limited (2096.HK) - Vision Statement

• Integrity: Upholding ethical practices, regulatory compliance, and transparent reporting across production, clinical development, and market activities.
• Innovation: Committing substantial resources to R&D to develop first-in-class and best-in-class therapies, biologics, and specialty generics.
• Collaboration: Building multi-stakeholder partnerships with hospitals, academic institutions, CROs, and global pharma to enhance clinical trials and commercialization.
• Accountability: Maintaining rigorous performance management, governance structures, and regular board and stakeholder reviews to align operations with strategic goals.
• Social Responsibility: Investing in patient-access programs, public health initiatives, and community healthcare projects to improve treatment accessibility.
• Sustainability: Integrating ESG principles-environmental stewardship, social impact, and strong governance-into R&D, manufacturing, and supply chain decisions.

• Increase R&D intensity to 15%+ of revenue within 3 years to accelerate first-in-class programs.
• Expand global partnerships to conduct 40% of late-stage trials with international CROs and hospitals.
• Improve ESG metrics: reduce carbon intensity per unit produced by 30% over 5 years and attain broader ESG disclosures aligned with SASB/TCFD.
• Broaden patient access initiatives: deploy patient assistance programs targeting a 20% increase in subsidized treatments in low-income regions.

• Targeted R&D investments in oncology biologics and neurology small molecules with multiple INDs filed in recent years.
• Collaborative deals with international biotechs and academic centers to co-develop assets and share trial expertise.
• Community health projects and patient assistance programs aimed at chronic disease management in under-served regions.